SEC Tracker
Get the app

Adaptive Biotechnologies ADPT

Julie Rubinstein reports executive trades

Julie Rubinstein, insider filing for ADPT

Form
4
Filed
Importance
Routine
  1. Julie Rubinstein, President and COO, sold 6,781 shares on Oct 14, 2026 at $25.57
  2. Sold 5,100 shares on Oct 14, 2026 at $25.82
  3. Purchased 11,881 shares on Oct 16, 2026 at $12.14
  4. Executed under a 10b5-1 trading plan adopted in 2025

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Adaptive Biotechnologies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  2. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  3. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  4. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025
  5. Avadel Pharmaceuticals AVDL

Data on this page was fetched . The filing on SEC.gov is the record.